Back

Changes in Cognitive Function in Patients with Subclinical Atrial Fibrillation Treated with Apixaban or Aspirin: A Sub-Study from the ARTESiA Trial

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies Cognitive Function and Autonomy in Patients with Atrial Fibrillation ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Lena Rivard

Montreal Heart Institute, Montreal (Canada)

4 More presentations in this session

Presentation thumbnail
Long-acting Factor XI Inhibition and Periprocedural Bleeding: A Secondary Analysis from AZALEA-TIMI 71
Doctor S. Patel (Boston, US)
Slides Video
Presentation thumbnail
Aspirin and hemocompatibility related adverse events after LVAD implantation in patients with diabetes mellitus, obesity and atrial fibrillation: the ARIES-HM3 randomized clinical trial
Doctor N. Uriel (New York, US)
Slides Video
Presentation thumbnail
Efficacy and safety of anticoagulation in patients with device-detected atrial fibrillation by indication for acetylsalicylic acid therapy
Professor R. Schnabel (Hamburg, DE)
Slides Video
Presentation thumbnail
The Association between Age and Clinical Outcomes in Patients with Subclinical Atrial Fibrillation Treated with Apixaban: Insights from the ARTESiA Trial
Associate Professor M. Proietti (Milan, IT)
Slides Video

Access the full session

Session thumbnail
Smaller trials, trial updates, and other studies on antiplatelet and antithrombotic therapies
Video

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources